Drug Target Review

JULY 23, 2024

Shortly after finishing my studies, I landed my first job in industry working on cell biology research for several disease indications. At the time, research and leadership roles in biotech/pharma industry were predominately held by men and there were not as many opportunities for career development and mentorship from women leaders.

Small Molecule 115

Small Molecule Targeted Protein Degradation Science Disease 115

The Pharma Data

DECEMBER 21, 2020

Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. . TOKYO and CAMBRIDGE, England , Dec. No further financial details are disclosed.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

The Pharma Data

SEPTEMBER 25, 2020

ICR and Cancer Research UK spinout closes Series B financing. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. Earlier this year, Monte Rosa announced that it had raised an initial £32.5m

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Clinical Development Disease 40

The Pharma Data

JULY 22, 2021

(NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. Chief Executive Officer at Arvinas.

Targeted Protein Degradation 52

Targeted Protein Degradation Therapies Clinical Trials Treatment 52

The Pharma Data

OCTOBER 15, 2020

a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry.

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule Science Disease 52

Drug Target Review

JULY 5, 2024

Since brain organoids can be derived from either diseased or healthy patients, they can recapitulate human (patho)physiology making them a better choice compared to mammalian cell systems that often fail to recapitulate the human phenotype. A significant challenge for the field is incorporating 3D models into high-throughput platforms.

Targeted Protein Degradation 64

Targeted Protein Degradation Drugs Disease FDA Approval 64

Elrig

MARCH 22, 2023

Over the two days, we’ll bring together academia, industry, and the vendor community to discuss recent advancements in two ultra-exciting areas of drug discovery and biological research: therapeutic oligonucleotides and chemical biology. Right now, targeted protein degradation is a critical focus topic across both industry and academia.

Targeted Protein Degradation 40

Targeted Protein Degradation Science Disease Laboratories 40

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. This targeted delivery allows enhanced therapeutic efficacy while reducing the harmful side effects commonly associated with traditional chemotherapy.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

SEPTEMBER 15, 2020

“ Amgen addresses important scientific questions to advance care and improve the lives of patients with serious diseases, including oncology, inflammation and cardiometabolic diseases, among others,” said Flavius Martin , vice president of Oncology, Inflammation and Site Head at Amgen South San Francisco.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Small Molecule Science 52

The Pharma Data

JANUARY 31, 2021

Joint drug discovery program to focus on a single ion channel that is a well-validated target for neurological diseases. They are well established drug targets, particularly in neurological and cardiovascular diseases, but many remain undrugged or poorly drugged, and may be tractable to structure-based approaches.

Structure Based Drug Design (SBDD) 52

Structure Based Drug Design (SBDD) Targeted Protein Degradation Drugs Disease 52

Sygnature Discovery

SEPTEMBER 25, 2023

Sygnature Discovery identifies potent SHP2 degrader compounds using its proprietary targeted protein degrader platform, CHARMED, in collaboration with Japanese specialty chemical company, UBE Corporation. Its staff of over 1,000, which includes 900 scientists, partners with global pharma, biotech and NFP organisations.

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule Science Disease 52

Drug Hunter

AUGUST 21, 2023

Obtaining adequate drug exposure in the brain is key to treating CNS diseases effectively. Prodrugs Remain in “Proof-of-Concept” Stages Prodrug strategies for CNS deliver have also been applied with varying success , with the most famous example being L-Dopa for Parkinson’s disease. Figure 14: Optimization of an NMT inhibitor by DNDi.

Drugs 206

Drugs Disease Targeted Protein Degradation Screening Hits 206